Landauer — Investor Presentation (August 2017)
24 slides from Landauer's investor presentation, Aug 10, 2017
Slide 1: Investor Presentation August 2017
LANDAUER’ Investor Presentation August 2017
Slide 2: Forward-looking statements
Some of the information shared here (including, in particular, the section titled “Fiscal Year 2017 Outlook”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and unce
Slide 3: Investment highlights
•The Joint Commission standards effective in July 2015 in the United States-Impacts 7,100 of the 20,500 U.S. healthcare organizations and programs, including hospitals, imaging clinics and certain ambulatory care centers-Estimated incremental cost of ~$30,000 annually for a hospital to comply with n
Slide 4: Global leader in occupational radiation products and services
.“Gold standard” in accuracy.Proprietary OSL crystal technology manufactured internally.Delivers wide-range of radiation monitoring:Dosimetry Reports with results are made available to the customer.Headquartered in Glenwood, IL.650 global employees.Only national network of imaging physicists.8 globa
Slide 5: Serving diverse end markets across three verticals
ProfessionalOfficesServing Diverse End Markets Across Three VerticalsAcute Care HospitalsProfessional OfficesIndustrialEnergyEmergency ResponseMilitary/National Security/DOEW:\Landauer\Investors\Investor deck\Images\73470968_5.jpgW:\Landauer\Investors\Investor deck\Images\L41513.2429.jpgPhysician Of
Slide 6: Global service labs and customer base
Service LabsWell-positioned to serve an expanding global customer base of ~75,000 clients ChicagoMexicoBrazilParisIstanbulBeijingTokyoAustralia
Slide 7: Domestic and international revenue and joint ventures
Additional $1.5 million in Equity Incomefrom International Joint Ventures80%20%FY GAAP 2016 RevenueDomestic U.S.InternationalJoint VentureLocationNagase-LANDAUERJapanEpsilon LANDAUERTurkeyAquilaNew MexicoEstimated 25% international market share provides ample room for continued growth
Slide 8: U.S. healthcare trends are fueling opportunity
U.S. Healthcare Trends are Fueling OpportunityIncreasingly complex and multi-dimensional radiation management landscape creates need for integrated, enterprise-wide solutions Tougher State Regulations Emerging•Pennsylvania•California•Massachusetts•Rhode Island•TexasHealthcare Consolidation•Larger bu
Slide 9: Uniquely positioned to capitalize on demand for solutions
Reports:Necessary for complianceAnalytics:Context to informationBenchmarkingRelevance to peersTraining:Assures compliance and patientoutcomesContinuous Improvement:Integrated data across the enterpriseUniquely Positioned to Capitalize on Demand for SolutionsCombining products, services, data and ana
Slide 10: Connect, integrate, expand beyond dose
.Shift the market focus .Simple dose focus .Continuous management of radiation safety.Better equip customers to monitor and control employee exposure and meet increasing compliance regulations.Leverage digital-based platform to grow offering of tailored products and services designed to better conne
Slide 11: Verifii digital platform
.Provides customers with a scalable, digital platform that connects employees to their environment .Eliminates fragmented manual processes enabling focus on building a robust radiation management solution.Timely radiation data adds value to customers by allowing them to take targeted actions for pra
Slide 12: How Verifii works
Real-time and historic data & analytics are available to client via web & mobile appsAllows customers to track trends, monitor event specific dose levels and enact behavioral changes to better manage long-term exposure Data is processed and stored in the cloudDosimeter connects via Bluetooth LE to d
Slide 13: Growth opportunities across hospitals, professional offices, industrial
.Virtual compliance solution for smaller offices that do not have an existing function in place.340,000 sites across Veterinarians, Medical, Dental and Chiropractic practices.6% estimated U.S. market share.Increasing regulations and use of advanced imaging equipment driving need for radiation safety
Slide 14: Capital allocation priorities
.Core business investments focused on top and bottom line growth.Emphasis on higher margin, annuity-style opportunities.Commercialization of next generation digital dosimetry platform while transitioning from current OSL crystal-based platform.Management compensation tied to ROIC.Long-term target of
Slide 15: Investment highlights summary
•The Joint Commission standards effective in July 2015 in the United States -Impacts 7,100 of the 20,500 U.S. healthcare organizations and programs, including hospitals, imaging clinics and certain ambulatory care centers-Estimated incremental cost of ~$30,000 annually for a hospital to comply with
Slide 16: Financial Overview
LANDAUER’ Financial Overview
Slide 17: Revenue history and recurring revenue
.Approximately 90% of revenue derived from subscriptions and is recurring in nature.2016 Revenues of $149.2 million impacted by 2015 Radon divestiture and 2016 Medical Products divestiture; pro forma 2016 revenues increased 4.8%.Contract with U.S. Army, Reserve and National Guard to replace its anti
Slide 18: Key Q3 FY 2017 financial drivers
$37.9Key Q3 FY 2017 Financial Drivers•Revenue of $39.9 million in the third quarter of fiscal 2017 includes ($0.8 million) impact of our divested Medical Products business•Military product sales increased $0.7 million compared to the prior year due to timing of shipments•Medical Physics revenues gre
Slide 19: Q3 non-GAAP reconciliation
* Non-GAAP financial measure($ Millions)Q3 FY2017As ReportedQ3 FY2017 Medical Products AdjustmentQ3 FY2017 Comparable, Excluding Divestiture*Revenue$39.9$ -$39.9Operating Income$8.6$ -$8.6($ Millions)Q3 FY2016As ReportedQ3 FY2016 Medical Products AdjustmentQ3 FY2016 Comparable, Excluding Divestiture
Slide 20: FY2016 and FY2015 non-GAAP reconciliation
* Non-GAAP financial measure($ Millions)FY2016As ReportedFY2016 Medical Products AdjustmentFY2016 Radon AdjustmentFY2016 Comparable, Excluding Divestitures *Revenue$149.2$(5.8)$(0.1)$143.3Operating Income$26.6$(1.0)$(0.1)$25.5($ Millions)FY2015As ReportedFY2015 Medical Products AdjustmentFY2015 Rado
Slide 21: Fiscal Year 2017 Outlook
*Non-GAAP financial measure.EPS for the first nine months of the year have been positively impacted by a one-time tax benefit and by equity earnings at joint ventures favorably impacted by capital salesFiscal Year 2017 Outlook($ Millions)FY 2016 ActualImpact of DivestedBusiness, Gain on Divestiture
Slide 22: Appendix
LANDAUER’ Appendix
Slide 23: Business facts and fiscal 2016 financial highlights
IDN HospitalsBusiness FactsProven Technology PlatformFiscal 2016 Financial HighlightsDiverse Markets.$149.2 Million in Annual Revenue .$28.9 Million in International Sales.~ 90% Recurring Revenues.$41.2 Million in Adjusted EBITDA .Adjusted EBITDA margin 27.6%.Headquartered in Glenwood, IL.Founded in
Slide 24: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial MeasuresManagement believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: Pro Forma Revenue and Pro Forma Operating Income.The Pro Forma Reven